Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Gap Down – Should You Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTPGet Free Report) shares gapped down before the market opened on Wednesday . The stock had previously closed at $0.4687, but opened at $0.4525. Elite Pharmaceuticals shares last traded at $0.4798, with a volume of 201,662 shares changing hands.

Elite Pharmaceuticals Price Performance

The business’s 50-day moving average price is $0.50 and its 200 day moving average price is $0.57. The company has a market capitalization of $486.70 million, a P/E ratio of 45.24 and a beta of 0.32. The company has a quick ratio of 6.34, a current ratio of 8.04 and a debt-to-equity ratio of 0.06.

About Elite Pharmaceuticals

(Get Free Report)

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

Featured Stories

Receive News & Ratings for Elite Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elite Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.